MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 584741 | Name: Miramistin

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Miramistin has been used in Russia and Ukraine as an antiseptic mean for individual prophylaxis of venereal diseases and for the treatment of genitourinary tract and other systems infections.

Chemical Structure

Miramistin
Miramistin
CAS#15809-19-5

Theoretical Analysis

MedKoo Cat#: 584741

Name: Miramistin

CAS#: 15809-19-5

Chemical Formula: C26H47ClN2O

Exact Mass: 438.3377

Molecular Weight: 439.13

Elemental Analysis: C, 71.12; H, 10.79; Cl, 8.07; N, 6.38; O, 3.64

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
15809-19-5 394211-21-3 (H2O)
Synonym
Miramistin; Miramystin
IUPAC/Chemical Name
Benzenemethanaminium, N,N-dimethyl-N-(3-((1-oxotetradecyl)amino)propyl)-, chloride
InChi Key
JQQZCIIDNVIQKO-UHFFFAOYSA-N
InChi Code
InChI=1S/C26H46N2O.ClH/c1-4-5-6-7-8-9-10-11-12-13-17-21-26(29)27-22-18-23-28(2,3)24-25-19-15-14-16-20-25;/h14-16,19-20H,4-13,17-18,21-24H2,1-3H3;1H
SMILES Code
CCCCCCCCCCCCCC(NCCC[N+](C)(C)CC1=CC=CC=C1)=O.[Cl-]
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 439.13 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Krivorutchenko IuL, Andronovskaia IB. [Prospects of using miramistin for individual prevention of sexual HIV transmission]. Lik Sprava. 2013 Mar;(2):117-23. Review. Russian. PubMed PMID: 24605621. 2: Danilova TA, Danilina GA, Adzhieva AA, Minko AG, Nikolaeva TN, Zhukhovitskii VG, Pronin AV. Effects of Miramistin and Phosprenil on Microbial Biofilms. Bull Exp Biol Med. 2017 Aug;163(4):439-442. doi: 10.1007/s10517-017-3823-x. Epub 2017 Aug 29. PubMed PMID: 28853090. 3: Fromm-Dornieden C, Rembe JD, Schäfer N, Böhm J, Stuermer EK. Cetylpyridinium chloride and miramistin as antiseptic substances in chronic wound management - prospects and limitations. J Med Microbiol. 2015 Apr;64(Pt 4):407-14. doi: 10.1099/jmm.0.000034. Epub 2015 Feb 13. PubMed PMID: 25681322. 4: Bazhanov NN, Aleksandrov MT, Cherkesov IV. [Use of miramistin for the treatment of patients with odontogenic phlegmons in the maxillofacial area]. Stomatologiia (Mosk). 2006;85(3):24-6. Russian. PubMed PMID: 16858318. 5: Krivorutchenko IuL, Krivoshein IuS, Andronovskaia IB, Nosik DN, Kalnina LB, Petrova MS. [The effect of fetal calf serum on the anti-HIV properties of miramistin]. Vopr Virusol. 1994 Nov-Dec;39(6):281-3. Russian. PubMed PMID: 7716926. 6: Vozianov AF, Krivoshein IuS, Pasechnikov SP, Kovalenko VV, Shatrov VA, Kuznetsova LV. [The effect of miramistin on the phagocytic activity of the urethral neutrophilic granulocytes in patients with chronic urethroprostatitis]. Vrach Delo. 1990 Oct;(10):113-5. Russian. PubMed PMID: 2080563. 7: Krivorutchenko IuL, KrivosheinIuS, Marennikova SS, Stepanova LG, Nosik DN, Kalnina LB, Rud'ko AP. [Study of the anti-HIV activity of miramistin]. Vopr Virusol. 1994 Nov-Dec;39(6):267-9. Russian. PubMed PMID: 7716921. 8: Vasil'eva TV, Raskidaĭlo AS, Arutcheva AA, Okropiridze GG, Petrakov AA, Urazgil'deev ZI, Kovalenko TM. [Antibacterial activity and clinical effectiveness of the new antiseptic miramistin]. Antibiot Khimioter. 1993 Aug-Sep;38(8-9):61-3. Russian. PubMed PMID: 8037581. 9: Tomashuk IP, Tomashuk II. [Clinical efficacy of alprostan in combination with "Bioptron-II" rays and iruxol-miramistin in the treatment of the diabetic foot complicated by atherosclerosis]. Klin Khir. 2001 Aug;(8):49-51. Russian. PubMed PMID: 11794113. 10: Krivorutchenko IuL. [Dose-dependent inactivation of extracellular human immunodeficiency virus by miramistin]. Vopr Virusol. 1998 May-Jun;43(3):122-4. Russian. PubMed PMID: 9702810. 11: Feoktistov V, Shakeyev K, Akhmetova S, Zhanassova M, Berkut M. [Local treatment of purulent-necrotic complications of diabetic foot syndrome]. Georgian Med News. 2014 Oct;(235):7-11. Russian. PubMed PMID: 25416209. 12: Shtyrlin NV, Sapozhnikov SV, Galiullina AS, Kayumov AR, Bondar OV, Mirchink EP, Isakova EB, Firsov AA, Balakin KV, Shtyrlin YG. Synthesis and Antibacterial Activity of Quaternary Ammonium 4-Deoxypyridoxine Derivatives. Biomed Res Int. 2016;2016:3864193. Epub 2016 Oct 5. PubMed PMID: 27800491; PubMed Central PMCID: PMC5069379. 13: Abdrahmanov RM, Fajzullina EV, Abdrahmanov AR, Haliullin RR. [To the issue of local treatment in combination therapy of chronic urethritis, associated with sexually transmitted infections]. Urologiia. 2015 Dec;(6):40-46. Russian. PubMed PMID: 28247679. 14: Fesenko VP, Krivoshein IuS, Mogiliastyĭ AA, Pavlova NV. [Use of miramistin in the treatment of experimental suppurative wounds in states of impaired peripheral blood circulation]. Klin Khir. 1996;(8):30-2. Russian. PubMed PMID: 9064139. 15: Shatrov VA, Krivoshein IuS, Kovalenko VV. [The effect of miramistin on the phagocytic activity of urethral neutrophil granulocytes]. Lab Delo. 1990;(4):55-6. Russian. PubMed PMID: 1695279. 16: Khan MA, Lian NA, Vakhova EL, Mikitchenko LI, Radetskaia LI. [Inhalation of Myramistin in the children presenting with acute respiratory diseases]. Vopr Kurortol Fizioter Lech Fiz Kult. 2015 May-Jun;92(3):35-39. doi: 10.17116/kurort2015335-39. Russian. PubMed PMID: 26285332. 17: Kriukov AI, Ivoĭlov AIu, Kunel'skaia VIa, Shadrin GB. [The experimentally-based rationale for the application of the new methods designed to treat fungal adenoiditis in the children]. Vestn Otorinolaringol. 2014;(4):49-51. Russian. PubMed PMID: 25377679. 18: Zhilyakova ET, Novikov OO, Akopova VV. Soft contact lenses as prospective transport systems for ophthalmology. Bull Exp Biol Med. 2013 Dec;156(2):290-4. PubMed PMID: 24319770. 19: Krivoshein IuS, Shatrov VA. [Effect of antimicrobial surface-active agents on the immune response to thymus-dependent antigen in mice]. Antibiot Khimioter. 1990 Jan;35(1):35-7. Russian. PubMed PMID: 2334243. 20: Mukhomedzianova LV, Vakhrushev SG, Polevshikov AV, Andrianova IV, Pozhilenkova EA. [Dynamics of immunological characteristics and investigation of apoptosis of palatal tonsillar lymphocytes in patients presenting with chronic tonsillitis and treated by conservative therapy]. Vestn Otorinolaringol. 2011;(3):13-7. Russian. PubMed PMID: 21720286.

View History

Micordilin

Micordilin